Drug Profile
Susoctocog alfa - Takeda
Alternative Names: B-Domain deleted recombinant porcine factor VIII (OBI-1); BAX 802; BAX801; Factor VIII - Ipsen; FVIII - Ipsen; OBI-1; Obizur; PFVIII; Porcine FVIII; Recombinant porcine factor VIII - Inspiration/Ipsen; RpfVIII; SHP672; TAK 672Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Emory University
- Developer Baxter International; Takeda
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Factor VII stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia A
Most Recent Events
- 30 Jun 2023 Preregistration for Haemophilia A (In the elderly, Treatment-experienced, In adults) in Japan (IV) (Takeda pipeline; July 2023)
- 29 Nov 2022 Takeda completes a phase II/III trial in Hemophilia A (In adults, In the elderly, Treatment experienced) in Japan (IV) (NCT04580407)
- 30 Jun 2022 Preregistration for Haemophilia A in China (IV) (Takeda pipeline; July 2023)